# Study on Sintilimab in Stage IV High Risk Neuroblastoma

> **NCT04412408** · EARLY_PHASE1 · UNKNOWN · sponsor: **Shanghai Children's Medical Center** · enrollment: 10 (estimated)

## Conditions studied

- Recurrent Stage IV High Risk Neuroblastoma

## Interventions

- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT04412408
- **Lead sponsor:** Shanghai Children's Medical Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-06-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2020-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04412408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04412408, "Study on Sintilimab in Stage IV High Risk Neuroblastoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04412408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*